Skip to search formSkip to main contentSkip to account menu

PR 350

Known as: PR-350 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

doranidazole

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Phase I/II trial of doranidazole (PR-350) and concurrent thoracic radiotherapy (TRT) in patients (pts) with locally advanced (LA) non-small cell lung cancer (NSCLC).
17064 Background: PR-350 was a nitoroimidazole derivative as a hypoxic cell radiosensitizer with low toxixity, developed by POLA… 
2005
2005
Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
We have investigated the radiosensitizing effect of doranidazole, a hypoxic cells radiosensitizer, using SCCVII tumor cells of… 
2002
2002
Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350).
This study was performed to confirm the radiation-chemical properties of the 2-nitroimidazole derivative doranidazole, (+/-)-(2RS… 
2002
2002
A nitroimidazole derivative, PR-350, enhances the killing of pancreatic cancer cells exposed to high-dose irradiation under hypoxia.
The radiosensitizing effects of PR-350, a nitroimidazole derivative, were examined concerning the cell killing of human… 
2001
2001
Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy
A phase Ia study of a 2-nitroimidazole nucleoside analog radiosensitizer doranidazole was conducted to evaluate its toxicity and… 
2001
2001
Effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine dehydrogenase activity and 5-fluorouracil pharmacokinetics
Abstract. This study was designed to investigate the effects of PR-350, a newly developed radiosensitizer, on dihydropyrimidine… 
2000
2000
Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
1999
1999
In vivo study of radiosensitizing effect of hypoxic cell radiosensitizer PR-350 on a human small cell lung cancer.
PURPOSE The purpose of this study was to clarify the utility of 1-(1',3',4'-Trihydroxy-2'-Butoxy) Methyl-2-Nitroimidazol (PR-350… 
1997
1997
Pharmacokinetics and radiosensitizing effect of PR-350.
PURPOSE The in vivo pharmacokinetics and sensitizing effects of PR-350, a newly developed, highly water-soluble radiosensitizer… 
1995
1995
Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)